Is non-invasive Cytosponge the holy grail for Barrett's neoplasia? (2022) Neurath M, Vieth M Journal article Lu-177-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial (2021) Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, et al. Journal article Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials (2021) Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M, Wimberger P, et al. Journal article Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial (2021) Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, et al. Journal article Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group (2021) Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, et al. Journal article, Review article Fertility Preservation in Childhood, Adolescent, and Young Adult Cancer 1 Fertility preservation for female patients with childhood , adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group (2021) Mulder RL, Font-Gonzalez A, Hudson MM, Santen HMV, Loeffen EAH, Burns KC, Quinn GP, et al. Journal article Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group (2021) Mulder RL, Font-Gonzalez A, Hudson MM, van Santen HM, Loeffen EA, Burns KC, Quinn GP, et al. Journal article, Review article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, et al. Journal article Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial (2020) Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, et al. Journal article